Text Size Normal Text Sizing Button Medium Text Sizing Button Large Text Sizing Button Text Contrast Normal Contrast Button Reverse Contrast Button Switch to Spanish Language Press Room Contact Us Sitemap Sign In Register
Link to Homepage About AHAF
Donate Now Get Involved  
Alzheimer's Disease Research Macular Degeneration Research National Glaucoma Research


Sign up for Email Notifications
If you would like to be notified when submission deadlines are announced please click on the link below.

Sign up for new RFP announcements and submission deadline notifications.

This email list is not sold or distributed, and serves only as an annual reminder of the availability of research funding through the American Health Assistance Foundation (www.ahaf.org). Please follow instructions on the notification emails for removal requests.
 
Researchers:
Have you heard a story, statistic, or discovery that might interest the public? Let us know about it!
 
AHAF Research Grants Funding
Grant Funding for Alzheimer's Research
Grant Funding for Macular Degeneration Research
Grant Funding for Glaucoma Research
 

  

National Glaucoma Research - Completed Award

Dr. Ian Trounce

Ian Trounce, Ph.D.

Centre for Eye Research Australia, The University of Melbourne
Melbourne, Australia

Title: The Effect Of Glaucoma Risk Factors On APP Processing In Retinal Ganglion Cells
Non-Technical Title: Alzheimer’s Disease Proteins In Glaucoma

Co-Investigator(s):
Jonathan Guy Crowston, M.D., Ph.D.
Centre for Eye Research Australia

Acknowledgements: Recipient of the Thomas R. Lee award for National Glaucoma Research
Duration: April 1, 2009 - October 31, 2011
Award Type: Standard
Award Amount: $94,834


Summary:

This study aims to study the influence of high eye pressure and increasing age, the two major risk factors for glaucoma, on how the "Alzheimer’s disease" protein “amyloid precursor protein” (APP) breaks down. These experiments will shed light on whether age-related changes in the way this protein functions account for the vulnerability of older eyes to glaucoma. If this is the case, then further work aimed at restoring APP will likely prove fruitful in developing new treatments for glaucoma.

Details:

Glaucoma and Alzheimer's disease are potentially debilitating degenerative diseases of the nervous system resulting in blindness and memory loss respectively. The frequency of both diseases increases dramatically as people age. The reason for this is not known, but if we can determine what makes nerves in older individuals vulnerable to these diseases, we may be able to identify robust treatments that protect nerves and prevent these diseases from progressing.

Recent evidence indicates that there may be similarities in the biological processes that result in nerve cell loss in both of these diseases. The breakdown of a protein, amyloid precursor protein, or APP, to a toxic by product (amyloid beta) is thought to contribute to memory loss in Alzheimer’s disease. Recent evidence indicates that this abnormal processing of APP may also occur in the retina in glaucoma raising the intriguing possibility that similar processes are responsible for both diseases. This would potentially have a major impact on glaucoma as it would provide a whole host of potential treatments that might protect the optic nerve and prevent vision loss in glaucoma.

This study aims to look at the influence of high eye pressure and increasing age, the two major risk factors for glaucoma, on APP breakdown. These experiments will shed light on whether age-related changes in APP processing account for the vulnerability of older eyes to glaucoma. If this is the case, then further work aimed at restoring APP and preventing amyloid beta will likely prove fruitful in developing new treatments for glaucoma.

This project brings together Prof. Jonathan Crowston a clinician-scientist with expertise in glaucoma and Dr. Ian Trounce a neuroscientist with expertise in Alzheimer's disease and APP. They have recognized a strong overlap of interests, and believe that combining their knowledge puts them in a strong position to address the following aims:

1. To determine whether elevated eye pressure alters APP breakdown in optic nerve cells in the mouse.

2. To determine whether increasing age alters APP breakdown in the optic nerve and whether aging makes the optic nerve more vulnerable to elevated eye pressure.

3. To determine whether restoration of APP can reverse the effect of aging and protect the optic nerve from damage

Progress Updates:

In this project, Drs. Ian Trounce, Jonathan Crowston and colleagues determined that the Alzheimer’s disease protein, called amyloid precursor protein (APP), may lose its protective function in the eye due to the glaucoma risk factors of increased age and increased eye pressure. These researchers have established the pathway that the APP protein triggers to protect nerve cells. In addition, they discovered that APP is abundant in the vitreous (the whitish gel that gives the eyeball its shape), which suggests it has an important role protecting the eye nerve cells that are lost to glaucoma. They also found that the protein decreases in abundance in the aging human eye. In the future, they will determine whether adding APP to the eye protects it from pressure-induced eye injury. These findings may provoke great interest from the wider brain disease research community due to the possible overlap of glaucoma and Alzheimer’s disease. Drs. Trounce and Crowston believe that drugs based on this new nerve protection pathway may be developed to prevent nerve cell loss in both of these diseases.